Jason Cavalier's most recent trade in Lyra Therapeutics Inc was a trade of 684 Common Stock done at an average price of $8.9 . Disclosure was reported to the exchange on July 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lyra Therapeutics Inc | Jason Cavalier | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.91 per share. | 10 Jul 2025 | 684 | 519,316 | - | 8.9 | 6,094 | Common Stock |
| Lyra Therapeutics Inc | Jason Cavalier | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2024 | 100,000 | 100,000 | - | 0 | Common Stock | |
| Lyra Therapeutics Inc | Jason Cavalier | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2024 | 200,000 | 200,000 | - | - | Stock Options | |
| Lyra Therapeutics Inc | Jason Cavalier | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 140,000 | 140,000 | - | - | Stock Option | |
| Lyra Therapeutics Inc | Jason Cavalier | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2022 | 15,605 | 15,605 | - | - | Stock Option | |
| Lyra Therapeutics Inc | Jason Cavalier | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2021 | 104,000 | 104,000 | - | - | Stock Options (Right to Buy) |